公开(公告)号：WO2013033569A1

公开(公告)日：2013-03-07

申请号：PCT/US2012/053398

申请日：2012-08-31

Applicant: INCYTE CORPORATION ,  LI, Yun-Long ,  YAO, Wenqing ,  COMBS, Andrew, P. ,  YUE, Eddy, W. ,  MEI, Song ,  ZHU, Wenyu ,  GLENN, Joseph ,  MADUSKUIE, Thomas, P., Jr. ,  SPARKS, Richard, B. ,  DOUTY, Brent

Inventor： LI, Yun-Long ,  YAO, Wenqing ,  COMBS, Andrew, P. ,  YUE, Eddy, W. ,  MEI, Song ,  ZHU, Wenyu ,  GLENN, Joseph ,  MADUSKUIE, Thomas, P., Jr. ,  SPARKS, Richard, B. ,  DOUTY, Brent

IPC: C07D471/04 ,  C07D487/04 ,  A61K31/519 ,  A61P35/00 ,  A61P29/00 ,  A61P27/00 ,  A61P19/00 ,  A61P1/00 ,  A61P17/00

CPC classification number: A61K31/519 ,  C07D471/04 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention provides heterocyclylamine derivatives of Formula (I): wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

Abstract translation: 本发明提供式（I）的杂环基胺衍生物：其中本文所定义的变量调节磷酸肌醇3-激酶（PI3K）的活性，并且可用于治疗与PI3Ks的活性相关的疾病，包括例如， 炎症性疾病，基于免疫的疾病，癌症和其它疾病。

公开(公告)号：WO2012087881A1

公开(公告)日：2012-06-28

申请号：PCT/US2011/065743

申请日：2011-12-19

Applicant: INCYTE CORPORATION ,  LI, Yun-Long ,  COMBS, Andrew P. ,  YUE, Eddy W. ,  MADUSKUIE JR., Thomas P. ,  SPARKS, Richard B.

Inventor： LI, Yun-Long ,  COMBS, Andrew P. ,  YUE, Eddy W. ,  MADUSKUIE JR., Thomas P. ,  SPARKS, Richard B.

IPC: C07D473/32 ,  A61K31/52 ,  A61P35/00

CPC classification number: C07D473/34 ,  A61K31/52 ,  A61K31/5377 ,  A61K45/06 ,  C07D473/32

Abstract: The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

Abstract translation: 本发明提供了调节磷酸肌醇3-激酶（PI3K）活性的N-（1-（取代苯基）乙基）-9H-嘌呤-6-胺衍生物，可用于治疗与 PI3Ks包括例如炎症性疾病，基于免疫的疾病，癌症和其它疾病。

公开(公告)号：WO2011069156A3

公开(公告)日：2011-08-11

申请号：PCT/US2010059093

申请日：2010-12-06

Applicant: UNIV DUKE ,  MATSUNAMI HIROAKI ,  LI YUN

Inventor： MATSUNAMI HIROAKI ,  LI YUN

IPC: C12N5/071 ,  C40B30/04

CPC classification number: C12Q1/6881 ,  C07K14/70571 ,  C12Q2600/136 ,  C12Q2600/156

Abstract: The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2, M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.

Abstract translation: 本发明涉及能够调节气味受体活化的多肽。 特别地，本发明提供能够增强加味剂受体活化的多肽（例如，3型毒蕈碱性乙酰胆碱受体M3）。 本发明还提供了检测各种加臭剂受体特异性配体的测定法。 此外，本发明提供了筛选多肽多态性和与气味受体激活相关的突变的方法（例如，与毒蕈碱性乙酰胆碱受体多肽（例如，M1，M2，M3，M4，M5）相关的多态性和突变）以及方法 筛选这些蛋白质的治疗剂，配体和调节剂。

公开(公告)号：WO2011084800A3

公开(公告)日：2011-07-14

申请号：PCT/US2010/061571

申请日：2010-12-21

Applicant: CARRIER CORPORATION ,  WU, Zhigang ,  FU, Degang ,  LI, Yun ,  MIJANOVIC, Stevo ,  PERKOVICH, Mark, J. ,  RADCLIFF, Thomas, D.

Inventor： WU, Zhigang ,  FU, Degang ,  LI, Yun ,  MIJANOVIC, Stevo ,  PERKOVICH, Mark, J. ,  RADCLIFF, Thomas, D.

IPC: F25D29/00

Abstract: A refrigeration system for a mobile unit includes a refrigeration loop (32), an air duct (70), a sensor (34) and a shock absorption unit (36). The refrigeration loop includes a compressor, a condenser, a refrigerant regulator and an evaporator (64). The air duct directs air from an air inlet to the evaporator, which air duct is defined by first and second panels. The sensor is disposed in the air duct. The shock absorption unit mounts the sensor to and provides a limited thermal conduction path between the sensor and the first panel (22).

公开(公告)号：WO2007081501A1

公开(公告)日：2007-07-19

申请号：PCT/US2006/048352

申请日：2006-12-19

Applicant: GENERAL ELECTRIC COMPANY ,  ZHANG, Anping ,  LI, Yun ,  FEIST, Thomas, Paul ,  HUBER, William, Hullinger

Inventor： ZHANG, Anping ,  LI, Yun ,  FEIST, Thomas, Paul ,  HUBER, William, Hullinger

IPC: B82B3/00 ,  H01L29/12 ,  H01L29/772 ,  H01L29/06

CPC classification number: H01L29/0665 ,  B82Y10/00 ,  B82Y25/00 ,  B82Y40/00 ,  H01F1/0072 ,  H01F1/009 ,  H01F1/405 ,  H01F41/30 ,  H01L29/0673 ,  H01L29/0676 ,  H01L29/068 ,  H01L29/16 ,  H01L29/20 ,  H01L29/22 ,  H01L29/24 ,  H01L29/772 ,  H01L33/18 ,  H01L2924/0002 ,  H01L2924/00

Abstract: A nanowire structure (10) and device for use in large area electronics and methods of making the same is provided. The nanowire structure (10) includes a nanowire (12) defining an axis (14), where the nanowire (12) includes a first end (16) and a second end (18). The first end (16) is axially spaced from the second end (18). Further, the nanowire structure (10) includes magnetic segments (22) that are coupled to the first (16) and second ends (18) of the nanowire. The structure allows for the alignent and contacting of the nanowire using local or external magnetic fielos.

Abstract translation: 提供了一种纳米线结构（10）和用于大面积电子器件的装置及其制造方法。 纳米线结构（10）包括限定轴线（14）的纳米线（12），其中纳米线（12）包括第一端（16）和第二端（18）。 第一端（16）与第二端（18）轴向间隔开。 此外，纳米线结构（10）包括耦合到纳米线的第一端（16）和第二端（18）的磁性段（22）。 该结构允许使用局部或外部磁粉的对准和接触纳米线。

公开(公告)号：WO2006041831A3

公开(公告)日：2006-12-21

申请号：PCT/US2005035661

申请日：2005-10-05

Applicant: SQUIBB BRISTOL MYERS CO ,  CORTE JAMES R ,  LI YUN-LONG

Inventor： CORTE JAMES R ,  LI YUN-LONG

IPC: C07D207/10 ,  A61K31/40 ,  A61K31/445 ,  C07D211/60

CPC classification number: C07D213/75 ,  C07D211/74 ,  C07D213/30 ,  C07D213/64 ,  C07D401/12

Abstract: The present application describes cyclic ß-amino acid derivatives or pharmaceutically acceptable salt forms thereof, wherein the central core is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Abstract translation: 本申请描述了环状β-氨基酸衍生物或其药学上可接受的盐形式，其中中心核心是非芳族碳环或杂环。 本发明的化合物可用作胰蛋白酶样丝氨酸蛋白酶的抑制剂，特别是因子Xa。

公开(公告)号：WO2006122214A2

公开(公告)日：2006-11-16

申请号：PCT/US2006/018147

申请日：2006-05-10

Applicant: HEALTH RESEARCH INC. ,  THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL ,  MOHLER, James, L. ,  TITUS, Mark ,  KOZYREVA, Olga ,  FORD, O'Harris,III ,  KAWINSKI, Elsbieta ,  LI, Yun

Inventor： MOHLER, James, L. ,  TITUS, Mark ,  KOZYREVA, Olga ,  FORD, O'Harris,III ,  KAWINSKI, Elsbieta ,  LI, Yun

IPC: C12Q1/68 ,  G01N33/574 ,  C12N9/02 ,  C12N15/861

CPC classification number: C12Q1/26 ,  C07K2319/21 ,  C07K2319/40 ,  C12N9/001 ,  C12N2799/022 ,  G01N33/57434

Abstract: The invention provides an isolated, novel steroid 5α-reductase enzyme termed SRD5AIIL The protein has an estimated molecular weight of 37 kDa and is capable of converting testosterone to dihydrotestosterone at a pH of about 7.0. Also provided is a method for identifying inhibitors of SRD5 AIII by contacting SRD5 AIII with a test compound and measuring the activity of the enzyme. A reduced activity relative to a control indicates that the test compound is an inhibitor of SRD5AIII. A method is also provided for detecting androgen stimulated prostate cancer or recurrent prostate cancer in an individual. The method comprises obtaining a prostate biopsy from an individual and determining the level of expression of SRD5ADI gene or protein relative to a normal control. An increased expression of SRD5AIII relative to the control is indicative of androgen stimulated prostate cancer or recurrent prostate cancer.

Abstract translation: 本发明提供了一种称为SRD5AIIL的分离的新型类固醇5a-还原酶。该蛋白质具有37kDa的估计分子量，并且能够在约7.0的pH下将睾酮转化为二氢睾酮。 还提供了通过将SRD5AIII与测试化合物接触并测量酶的活性来鉴定SRD5AIII的抑制剂的方法。 相对于对照的降低的活性表明测试化合物是SRD5AIII的抑制剂。 还提供了用于检测个体中激素刺激的前列腺癌或复发性前列腺癌的方法。 该方法包括从个体获得前列腺活检，并确定SRD5ADI基因或蛋白质相对于正常对照的表达水平。 SRD5AIII相对于对照的增加的表达指示雄激素刺激的前列腺癌或复发性前列腺癌。

公开(公告)号：WO2013106991A1

公开(公告)日：2013-07-25

申请号：PCT/CN2012/070449

申请日：2012-01-17

Applicant: HONEYWELL INTERNATIONAL INC. ,  MA, Qiurong ,  REN, Hongzhi ,  HUANG, Liuxin ,  YIN, Jun ,  GU, Wenjie ,  LI, Yun ,  ZHU, Xiaoxun ,  LIU, Huatao

Inventor： MA, Qiurong ,  REN, Hongzhi ,  HUANG, Liuxin ,  YIN, Jun ,  GU, Wenjie ,  LI, Yun ,  ZHU, Xiaoxun ,  LIU, Huatao

IPC: G06K7/10 ,  H04M1/02

CPC classification number: G06K7/1443 ,  G06K7/10722 ,  G06K7/10881 ,  H04M1/21 ,  H04M1/72522 ,  H04M2250/22 ,  Y10T29/49117

Abstract: A data entry and scanning apparatus that includes a commercially available mobile device wherein said commercially available mobile device with a touch screen display, a processor, and a wireless communications network access point, a scanning device, an interface, and a power source that external to the commercially available mobile device and connected to the interface, and a casing that does not cover the touch screen display.

Abstract translation: 一种包括市售移动设备的数据输入和扫描设备，其中所述具有触摸屏显示器，处理器和无线通信网络接入点，扫描设备，接口和电源的市售移动设备， 市售的移动设备并且连接到接口，以及不覆盖触摸屏显示器的外壳。

公开(公告)号：WO2011163195A1

公开(公告)日：2011-12-29

申请号：PCT/US2011/041202

申请日：2011-06-21

Applicant: INCYTE CORPORATION ,  LI, Yun-Long ,  COMBS, Andrew P.

Inventor： LI, Yun-Long ,  COMBS, Andrew P.

IPC: C07D473/34 ,  C07D519/00 ,  A61K31/52 ,  A61P35/00

CPC classification number: C07D473/34 ,  A61K31/52 ,  C07D519/00

Abstract: The present invention provides fused pyrrole derivatives of Formula (I) wherein V, W, X, Y, L, Q, Ar, Z, R 1 and R 6 are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

Abstract translation: 本发明提供式（I）的稠合吡咯衍生物，其中V，W，X，Y，L，Q，Ar，Z，R 1和R 6在本文中定义，其调节磷酸肌醇3-激酶（PI3K）的活性， 可用于治疗与PI3Ks的活性相关的疾病，包括例如炎性疾病，基于免疫的疾病，癌症和其它疾病。

公开(公告)号：WO2011069156A2

公开(公告)日：2011-06-09

申请号：PCT/US2010/059093

申请日：2010-12-06

Applicant: DUKE UNIVERSITY ,  MATSUNAMI, Hiroaki ,  LI, Yun

Inventor： MATSUNAMI, Hiroaki ,  LI, Yun

IPC: C12Q1/68

CPC classification number: C12Q1/6881 ,  C07K14/70571 ,  C12Q2600/136 ,  C12Q2600/156

Abstract: The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2, M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.

Abstract translation: 本发明涉及能够调节气味受体活化的多肽。 特别地，本发明提供能够增强气味受体活化的多肽（例如，3型毒蕈碱乙酰胆碱受体M3）。 本发明进一步提供了用于检测对各种气味受体特异性的配体的测定。 另外，本发明提供了筛选与气味受体激活相关的多肽多态性和突变（例如，与毒蕈碱性乙酰胆碱受体多肽（例如M1，M2，M3，M4，M5）相关的多态性和突变）的方法，以及方法 筛选治疗剂，配体和这些蛋白质的调节剂。